BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26351543)

  • 1. Mucormycosis during Imatinib treatment: case report.
    Crisan AM; Ghiaur A; Stancioaca MC; Bardas A; Ghita C; Manea CM; Ionescu B; Coriu D
    J Med Life; 2015; 8(3):365-70. PubMed ID: 26351543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of Bone Marrow Necrosis by Tyrosine Kinase Inhibitor Substitution in a Pediatric Patient With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
    Mikami T; Kato I; Oiki N; Okamoto S; Kamitori T; Tasaka K; Ogata H; Tanaka K; Umeda K; Hiramatsu H; Okamoto T; Adachi S; Takita J
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e539-e542. PubMed ID: 33843813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
    Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
    Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era].
    Dobashi N
    Rinsho Ketsueki; 2020; 61(9):1227-1235. PubMed ID: 33162520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
    J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
    Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R
    Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?
    Litzow MR
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):345-350. PubMed ID: 27890258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children].
    Guo Y; Liu TF; Ruan M; Yang WY; Chen XJ; Zhang L; Wang SC; Liu F; Zhang JY; Liu XM; Qi BQ; Zou Y; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Aug; 17(8):819-24. PubMed ID: 26287346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation.
    Fujimaki K; Hattori Y; Nakajima H
    Int J Hematol; 2018 Jun; 107(6):709-711. PubMed ID: 29188580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prolonged molecular response induced by imatinib in Philadelphia positive acute lymphoblastic leukemia A case report and brief review].
    Raissi A; Bouaouad M; Drideb NA; Jennane S; Mahtat el M; Doghmi K; Mikdame M
    Ann Biol Clin (Paris); 2015; 73(2):195-8. PubMed ID: 25847743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukemia.
    Salonen JH
    Acta Biomed; 2006; 77 Suppl 2():28-31. PubMed ID: 16918065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04.
    Manabe A; Kawasaki H; Shimada H; Kato I; Kodama Y; Sato A; Matsumoto K; Kato K; Yabe H; Kudo K; Kato M; Saito T; Saito AM; Tsurusawa M; Horibe K
    Cancer Med; 2015 May; 4(5):682-9. PubMed ID: 25641907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors.
    Yoshimura T; Nakane T; Hirose A; Koh H; Nakamae M; Aimoto M; Nishimoto M; Hayashi Y; Terada Y; Nakamae H; Hino M
    Osaka City Med J; 2013 Jun; 59(1):9-21. PubMed ID: 23909077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
    Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
    Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lim SN; Joo YD; Lee KH; Kim DY; Lee JH; Lee JH; Chi HS; Yun SC; Lee WS; Lee SM; Park S; Kim I; Sohn SK; Moon JH; Ryoo HM; Bae SH; Hyun MS; Kim MK; Kim HJ; Yang DH; Eom HS; Lee GW; Jung CW; Won JH; Kim H; Lee JH; Shin HJ; Jang DY
    Am J Hematol; 2015 Nov; 90(11):1013-20. PubMed ID: 26228525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sustained molecular remission with a tyrosine kinase inhibitor alone for seven months in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Takahashi T; Shigeoka T; Suzukawa M; Ishido A; Tominaga T
    Rinsho Ketsueki; 2013 Feb; 54(2):210-3. PubMed ID: 23470829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.